AVASTIN - AVASTIN - CT 5390 - English version

Has

Description

Introduction AVASTIN 25 mg/ml Pack of 1 vial containing 4 ml (CIP: 566 200-7) Pack of 1 vial containing 16 ml (CIP: 566 201-3) Posted on May 21 2009 Active substance (DCI) bevacizumab ATC Code L01XC07 Laboratory / Manufacturer ROCHE AVASTIN 25 mg/ml Pack of 1 vial containing 4 ml (CIP: 566 200-7) Pack of 1 vial containing 16 ml (CIP: 566 201-3) Posted on May 21 2009

Sujets

• Cancer du sein
• Cancer
• Médecine

Informations

• Publié par: haute-autorite-sante-cancers
• Publié le: 14 mai 2008
• Nombre de lectures: 29
• Licence : En savoir +
  Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
• Langue: English

Extrait

 

 

 

 

The legally binding text is the original French version

TRANSPARENCY COMMITTEE

OPINION

 

  14 May 2008         AVASTIN 25 mg/ml Pack of 1 vial containing 4 ml (CIP: 566 200-7) Pack of 1 vial containing 16 ml (CIP: 566 201-3)   Applicant: ROCHE   bevacizumab    List I Medicinal product reserved for hospital use. To be prescribed only by specialists or oncologists or cancer specialists   ATC Code: L01XC07   Dates of MA and variations: Centralised MA: 12 January 2005: metastatic colorectal cancer MA variations: 27 March 2007: extension of indication: metastatic breast cancer 21 August 2007: extension of indication: to be assessed   Reason for request: Inclusion on the list of medicines approved for use by hospitals in the extension of indication “Avastin, in addition to platinum-based chemotherapy, is indicated for first line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology”.                     Health Technology, Economic and Public Health Assessment Division

   

1